Bayer has appointed Heiko Schipper to the Board of Management of Bayer effective March 1, 2018. He will succeed Erica Mann as the head of the Consumer Health Division, which…
Merck & Co. and Cue Biopharma, a Cambridge, Massachusetts-headquartered immunotherapy company, have signed a research collaboration and license agreement in a deal worth up to $374 million. Under the deal,…
FDA Issues Final Guidance for Generic Drugs with Abuse-Deterrent Properties
The US Food and Drug Administration has issued final guidance, General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products, to assist companies in their development…
Teva Announces New Operating Structure, Leadership Changes
Teva Pharmaceutical Industries has announced a new organization and leadership structure to be implemented immediately. This news follows an announcement by Teva in August 2017 of total staff reductions of…
Amsterdam Selected as New HQ for European Medicines Agency Post Brexit
The European Medicines Agency (EMA), currently headquartered in London, will relocate to Amsterdam, the Netherlands. Amsterdam was one of 19 cities in the European Union (EU) that bid to host…
The European Commission (EC) has approved Boehringer Ingelheim’s (BI’s) Cyltezo (adalimumab), a biosimilar to AbbVie’ Humira (adalimumab), for treating multiple chronic inflammatory diseases in adults and children. Humira is AbbVie’s…
Bayer has signed an agreement with Loxo Oncology, a Stamford, Connecticut-based biopharmaceutical company, to develop Loxo’s larotrectinib (LOXO-101) and LOXO-195 for treating patients with cancers harboring tropomyosin receptor kinase (TRK)…
Bill Gates Plans $50-Million Investment to Combat Alzheimer’s Disease
Bill Gates plans to invest $50 million in the Dementia Discovery Fund (DDF), a private fund working to diversify the clinical pipeline and identify new targets for treating Alzheimer’s disease.…
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Otsuka, Allergan, and Bristol-Myers Squibb. Editor’s Note: This article was updated on a continuous basis…
A roundup of the latest market developments from the pipelines of the pharmaceutical majors, featuring news from GlaxoSmithKline, Otsuka, and Merck & Co. Editor’s Note: This article was updated on…